{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027295","form_type":"8-K","ticker":"SONM","cik":"0001178697","company_name":"DNA X, Inc.","filed_at":"2026-06-04T20:48:21+00:00","discovered_at":"2026-06-04T20:49:00.303546+00:00","generated_at":"2026-06-04T21:13:53.740435+00:00","sec_items":["1.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DNA X terminates $500M equity line with Chardan Capital Markets","bullets":["Terminated ChEF Purchase Agreement with Chardan Capital Markets, effective May 28, 2026.","Original agreement committed Chardan to purchase up to $500M of common stock.","Registration Rights Agreement also terminated.","No replacement financing disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027295","json":"https://secwatch.observer/filing/0001493152-26-027295.json","markdown":"https://secwatch.observer/filing/0001493152-26-027295.md","text":"https://secwatch.observer/filing/0001493152-26-027295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226027295/0001493152-26-027295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226027295/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:13:53.740435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"083a4f9ed8b474755e5245443a2f26e967be0f65","claim":"DNA X, Inc. terminated Registration Rights Agreement with Chardan Capital Markets LLC (effective 2026-05-28).","evidence_excerpt":"On May 29, 2026, the Company and Chardan entered into a letter agreement pursuant to which they agreed, among other things, to terminate, effective as of 5:00 p.m., New York City time, on May 28, 2026, the ChEF Agreement and Registration Rights Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226027295/0001493152-26-027295-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"Chardan Capital Markets LLC"},{"label":"Effective","value":"2026-05-28"}],"fact_type":"material_agreement"},{"claim_id":"d2eb912dc3aaaca599a4228eb166a8d38181fe04","claim":"DNA X, Inc. terminated ChEF Purchase Agreement with Chardan Capital Markets LLC valued at up to $500 million (effective 2026-05-28).","evidence_excerpt":"On May 29, 2026, the Company and Chardan entered into a letter agreement pursuant to which they agreed, among other things, to terminate, effective as of 5:00 p.m., New York City time, on May 28, 2026, the ChEF Agreement and Registration Rights Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178697/000149315226027295/0001493152-26-027295-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Chardan Capital Markets LLC"},{"label":"Value","value":"up to $500 million"},{"label":"Effective","value":"2026-05-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}